Symbols

Adaptive 2025 Q3 Earnings Surges to Profitability with 129.7% Net Income Increase

Generated by AI AgentAinvest Earnings Report DigestReviewed byAInvest News Editorial Team

Thursday, Nov 6, 2025 8:24 am ET1min read

Aime Summary

- Adaptive Biotechnologies (ADPT) reported a 129.7% YoY net income increase and 38.15% revenue beat in Q3 2025, driven by MRD segment growth and clonoSEQ test expansion.

- MRD revenue reached $56.79M with 38% YoY clonoSEQ volume growth, supported by NCCN guideline updates and $33.74M in collaboration revenue.

- CEO Chad Robins emphasized disciplined execution, R&D efficiency, and 2026 growth optimism, while shares rose 12.3% post-earnings on strong investor confidence.

- Zacks Rank #3 (Hold) reflects cautious optimism, with focus on long-term innovation and market expansion amid expanded immune medicine partnerships.

Adaptive Biotechnologies (ADPT) delivered a standout Q3 2025 performance, exceeding revenue estimates by 38.15% and reporting a net income turnaround of 129.7% year-over-year. , signaling improved operational discipline. CEO highlighted MRD’s profitability milestones and strategic focus on scaling EMR integrations and immune medicine programs.

Revenue

, . The MRD segment led growth with $56.79 million in revenue, driven by 38% year-over-year clonoSEQ test volume expansion and NCCN guideline updates. Service revenue contributed $50.29 million, . , supported by $33.74 million in collaboration revenue and $3.44 million in service revenue.

Earnings/Net Income

Adaptive returned to profitability with net income of $9.54 million in Q3 2025, . , . , underscoring its operational turnaround.

Post-Earnings Price Action Review

, 2025, . , reflecting strong investor confidence in the company’s profitability milestones and revised guidance. , with bullish sentiment tied to MRD’s scalable growth and pharma partnership potential.

CEO Commentary

, driven by disciplined execution and clonoSEQ adoption. , . Robins expressed optimism about 2026 momentum, stressing long-term value creation through R&D efficiency and operational execution.

Guidance

, citing stronger clinical performance and milestone revenue. . , reinforcing confidence in sustained growth.

Additional News

, . , boosting clonoSEQ adoption. Additionally, , reflecting expanded partnerships in immune medicine.

, . . With a Zacks Rank #3 (Hold), investors await further clarity on long-term innovation and market expansion.

Ainvest Earnings Report Digest

Get noticed about the list of notable companies` earning reports after markets close today and before markets open tomorrow.

Latest Articles

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments

﻿

Add a public comment...

No comments yet

AInvest
PRO

Editorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process. While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context. Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue